Login to Your Account



ASCO 2011 Annual Meeting

Incyte, YM Prepare the Field for a Myelofibrosis Battle

By Mari Serebrov


Tuesday, June 7, 2011
With the submission of its new drug application for ruxolitinib, Incyte Corp. is counting on having the myelofibrosis field to itself for a few years with a first-in-class treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription